BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 21685036)

  • 1. Classical-type invasive lobular carcinoma with HER2 overexpression: clinical, histologic, and hormone receptor characteristics.
    Yu J; Dabbs DJ; Shuai Y; Niemeier LA; Bhargava R
    Am J Clin Pathol; 2011 Jul; 136(1):88-97. PubMed ID: 21685036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?
    Fadare O; Wang SA; Hileeto D
    Hum Pathol; 2008 Mar; 39(3):331-6. PubMed ID: 18261623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of prolonged fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast cancer: a prospective study.
    Tong LC; Nelson N; Tsourigiannis J; Mulligan AM
    Am J Surg Pathol; 2011 Apr; 35(4):545-52. PubMed ID: 21358301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.
    Fernandes RC; Bevilacqua JL; Soares IC; Siqueira SA; Pires L; Hegg R; Carvalho FM
    Histopathology; 2009 Sep; 55(3):346-52. PubMed ID: 19723150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histologic subtypes of invasive lobular carcinoma in correlation with tumor status and hormone receptors.
    Mise I; Vucić M; Maricević I; Sokcević M; Curić-Jurić S
    Acta Clin Croat; 2010 Sep; 49(3):275-81. PubMed ID: 21462816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pleomorphic lobular carcinoma in situ (PLCIS) on breast core needle biopsies: clinical significance and immunoprofile.
    Chivukula M; Haynik DM; Brufsky A; Carter G; Dabbs DJ
    Am J Surg Pathol; 2008 Nov; 32(11):1721-6. PubMed ID: 18769331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
    Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
    J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of E-cadherin and c-erbB-2/HER-2/neu oncoprotein in high-grade breast cancer.
    Turashvili G; Bouchalova K; Bouchal J; Kolar Z
    Cesk Patol; 2007 Jul; 43(3):87-92. PubMed ID: 17821836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seven-year survey of classical and pleomorphic invasive lobular breast carcinomas in women from southeastern Serbia: Differences in clinicopathological and immunohistochemical features.
    Ilic IR; Djordjevic NP; Randjelovic PJ; Stojanovic NM; Radulovic NS; Ilic RS
    J BUON; 2016; 21(5):1113-1120. PubMed ID: 27837612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Invasive pleomorphic lobular carcinoma, negative for ER, PR and Her/2neu--a case report.
    Manucha V; Khilko N; Reilly K; Zhang X
    Int J Clin Exp Pathol; 2011 Jan; 4(2):200-5. PubMed ID: 21326816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ductal invasive mammary carcinoma--clinicopathological prognostic factors related to immunohistochemical expression of hormonal receptors and Her2/neu oncoprotein.
    Recăreanu F; Simionescu C; Georgescu CV; Pirici E
    Rom J Morphol Embryol; 2011; 52(3 Suppl):1059-64. PubMed ID: 22119825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histology and immunophenotype of invasive lobular breast cancer. daily practice and pitfalls.
    Varga Z; Mallon E
    Breast Dis; 2008-2009; 30():15-9. PubMed ID: 19850991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency, Clinicopathologic Characteristics, and Follow-up of HER2-Positive Nonpleomorphic Invasive Lobular Carcinoma of the Breast.
    Zhang H; Moisini I; Ajabnoor RM; Turner BM; D'aguiar M; Cai X; Gao S; Yang Q; Wang X; Schiffhauer L; Hicks DG
    Am J Clin Pathol; 2020 Apr; 153(5):583-592. PubMed ID: 31786600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lobular intraepithelial neoplasia [lobular carcinoma in situ] with comedo-type necrosis: A clinicopathologic study of 18 cases.
    Fadare O; Dadmanesh F; Alvarado-Cabrero I; Snyder R; Stephen Mitchell J; Tot T; Wang SA; Ghofrani M; Eusebi V; Martel M; Tavassoli FA
    Am J Surg Pathol; 2006 Nov; 30(11):1445-53. PubMed ID: 17063087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequent alterations of HER2 through mutation, amplification, or overexpression in pleomorphic lobular carcinoma of the breast.
    Lien HC; Chen YL; Juang YL; Jeng YM
    Breast Cancer Res Treat; 2015 Apr; 150(2):447-55. PubMed ID: 25773929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pleomorphic lobular carcinoma: a distinctive clinical and molecular breast cancer type.
    Monhollen L; Morrison C; Ademuyiwa FO; Chandrasekhar R; Khoury T
    Histopathology; 2012 Sep; 61(3):365-77. PubMed ID: 22486370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
    Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K
    Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
    Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
    Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.